Adage Capital Partners Cuts Fulcrum Therapeutics Stake to 1.9%

TL;DR

**Adage Capital Partners just trimmed its stake in Fulcrum Therapeutics to 1.9%.**

AI Summary

Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, disclosing its ownership in Fulcrum Therapeutics, Inc. As of December 31, 2023, Adage Capital Partners, L.P. beneficially owned 1,506,422 shares of Fulcrum Therapeutics' Common Stock, representing 1.9% of the company. This is a decrease from their previous filing, indicating they have reduced their stake in the pharmaceutical company. This matters to investors because a significant institutional investor reducing its position could signal a change in their outlook on Fulcrum Therapeutics' future prospects.

Why It Matters

A major institutional investor, Adage Capital Partners, has reduced its holdings in Fulcrum Therapeutics, which could be interpreted by the market as a loss of confidence or a strategic portfolio rebalancing.

Risk Assessment

Risk Level: medium — While not a massive sell-off, a reduction in stake by an institutional investor like Adage Capital Partners could indicate potential concerns or a shift in investment strategy, posing a medium risk to current shareholders.

Analyst Insight

An investor should monitor Fulcrum Therapeutics' upcoming news and financial reports to understand if Adage Capital Partners' reduced stake is an isolated portfolio adjustment or indicative of broader concerns about the company's fundamentals or pipeline. It would be prudent to research any recent company developments around December 31, 2023, that might have influenced this decision.

Key Numbers

• 1,506,422 — Shares Beneficially Owned (This is the total number of shares of Fulcrum Therapeutics' Common Stock held by Adage Capital Partners, L.P. as of December 31, 2023.)
• 1.9% — Percentage of Class (This represents the percentage of Fulcrum Therapeutics' Common Stock that Adage Capital Partners, L.P. beneficially owns, indicating a reduced stake.)
• $0.001 — Par Value per Share (This is the nominal par value of Fulcrum Therapeutics' Common Stock, as stated in the filing.)

Key Players & Entities

• Adage Capital Partners, L.P. (company) — reporting person and institutional investor
• Fulcrum Therapeutics, Inc. (company) — subject company whose shares are being reported
• 1,506,422 (dollar_amount) — number of shares beneficially owned
• 1.9% (dollar_amount) — percentage of class beneficially owned
• December 31, 2023 (date) — date of event requiring the filing
• February 7, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Other institutional investors may review their positions in Fulcrum Therapeutics following Adage Capital Partners' reduction. (Fulcrum Therapeutics, Inc.) — medium confidence, target: Q1 2024
• Fulcrum Therapeutics' stock price might experience minor downward pressure or increased volatility in the short term due to this disclosure. (Fulcrum Therapeutics, Inc.) — low confidence, target: February 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0425sc13ga.htm (SC 13G/A) — 97KB
• 0000902664-24-001172.txt ( ) — 99KB

(a)

Item 1(a). NAME OF ISSUER The name of the issuer is Fulcrum Therapeutics, Inc. (the “ Company ”).

(b)

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES The Company’s principal executive offices are located at 26 Landsdowne Street, Cambridge, Massachusetts 02139.

(a)

Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ ACP ”) with respect to the Common Stock directly owned by it; (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACPGP ”), as general partner of ACP with respect to the Common Stock directly owned by ACP; (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACA ”), as managing member of ACPGP, general partner of ACP, with respect to the Common Stock directly owned by ACP; (iv) Robert Atchinson (“ Mr. Atchinson ”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP; and (v) Phillip Gross (“ Mr. Gross ”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the “ Reporting Persons .” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

(c)

Item 2(c). CITIZENSHIP ACP is a limited partnership organized under the laws of the State of Delaware. ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES Common stock, par value $0.001 per share (the “ Common Stock ”).

(e)

Item 2(e). CUSIP NUMBER 359616109 CUSIP No. 359616109 13G/A Page 8 of 10 Pages Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance company as defined in Section 3(a)(19) of the Act; (d) Investment company registered under Section 8 of the Investment Company Act of 1940; (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable. Item 4. A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C. (a) Amount beneficially owned: 1,506,422 (b) Percent of class: 2.44%. The percentage set forth in this Schedule 13G/A is calculated based upon, 61,822,554 shares of Common Stock as of October 31, 2023 as reported to be outstanding in the Company’s Quarterly Report on Form 10-Q for the Quarterly Period ended September 30, 2023 and filed with the Securities and Exchange Commission on November 7, 2023. (c) (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 1,506,422 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispos

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 7, 2024 ADAGE CAPITAL PARTNERS, L.P. By: Adage Capital Partners GP, L.L.C., its general partner By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL PARTNERS GP, L.L.C. By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL ADVISORS, L.L.C. /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ROBERT ATCHINSON /s/ Robert Atchinson ROBERT ATCHINSON, individually PHILLIP GROSS /s/ Phillip Gross PHILLIP GROSS, individually

View Full Filing

View this SC 13G/A filing on SEC EDGAR